VICTORIA, Sept. 1, 2017 /CNW/ - Emerald Health
Therapeutics, Inc. (TSXV: EMH; OTCQX: EMHTF) ("Emerald" or the
"Company") announces that it has engaged PCG Advisory Group
("PCG"), a New York, New
York based investor relations firm, to provide investor
relations and strategic communications services to the Company,
subject to TSX Venture Exchange acceptance.
PCG has been engaged for an initial term of six months and will
be entitled to receive a monthly fee of US$6,500. The agreement will automatically
renew on a monthly basis following the initial term and may be
terminated by the Company upon 30 days' notice following the
initial term. In addition, the Company has agreed to a
one-time grant of options to purchase up to 100,000 shares of the
Company exercisable for a period of 5 years at a price equal to the
closing price of the common shares on the TSX Venture Exchange on
the date of issuance. The options shall become vested and
exercisable in equal quarterly instalments over 2 years, provided
that PCG is continuing to provide services on the date of each
vesting increment. The options shall be subject to the
applicable policies of the TSX Venture Exchange.
PCG currently has no direct or indirect interest in the
securities of the Company, or any right or intent to acquire such
an interest except pursuant to the exercise of the above referenced
options.
The appointment of PCG as an investor relations consultant of
the Company and the granting of the options remain subject to
regulatory acceptance of applicable filings with the TSX Venture
Exchange.
About Emerald Health Therapeutics, Inc.
Emerald operates primarily through Emerald Health Botanicals
Inc. ("Botanicals"), a wholly owned subsidiary of the
Company and a Licensed Producer under the Access to Cannabis for
Medical Purposes Regulations (ACMPR). Botanicals is authorized to
produce and sell both dried medical cannabis flowers and medical
cannabis oils in Canada.
Botanicals currently operates an indoor facility in Victoria, British Columbia, with plans for
expansion on a 32-acre property in Metro Vancouver and a joint
venture with Village Farms utilizing 25 acres of greenhouse complex
in Delta, BC. Botanicals is one of
Canada's most medically focused
licensed producers, with a team of highly qualified management
experienced in pharmaceutical drug discovery, development and
distribution. Emerald's vision is to be a leading provider of
cannabis products through its production capabilities, proprietary
genetics and intellectual property, value added products and
branding, and superb customer experience.
Please visit https://www.emeraldhealth.ca/ for more
information.
About PCG Advisory Group
Founded in 2008 and headquartered in New York City, PCG Advisory Group is dedicated
to the delivery of top tier investor relations, strategic advisory,
communications, and innovative digital media services for the micro
and small cap public company marketplace. PCG has extensive
experience with life sciences, technology, energy and other
emerging growth companies, both in the US and internationally.
PCG's team of senior level professionals bring many years of direct
advisory experience, along with unique and high quality
relationships amongst the investment and media communities. PCG's
primary focus is building a shareholder base and expanding market
awareness through very professional methods and initiatives. PCG's
Capital Markets Advisory Services include overall investor
marketing and communications strategy development to increase and
leverage awareness, visibility and credibility. PCG's Social and
Digital Media services include maximizing social and professional
digital media channels to effectively and accurately communicate
clients' specific opportunities. www.pcgadvisory.com
Cautionary Statements Regarding Forward Looking
Information
Certain statements in this press release constitute
forward-looking statements, within the meaning of applicable
securities laws. All statements that are not historical facts,
including without limitation, statements regarding future
estimates, plans, programs, forecasts, projections, objectives,
assumptions, expectations or beliefs of future performance, are
"forward-looking statements".
We caution you that such "forward-looking statements" involve
known and unknown risks and uncertainties that could cause actual
and future events to differ materially from those anticipated in
such statements. Forward-looking statements include, but are not
limited to, statements regarding the Company's plans for expansion;
and the Company's vision to be a leading provider of cannabis.
The Company does not intend, and does not assume any obligation,
to update these forward-looking statements except as required by
law. These forward-looking statements involve risks and
uncertainties relating to, among other things, the potential
offering of any securities by the Company; variations in market
conditions; failure of the federal government to approve
legislation legalizing sales of non-therapeutic adult-use cannabis;
failure to obtain Health Canada and other regulatory approvals;
failure to obtain necessary financing; results of production and
sale activities; the Company's historical experience with medical
marijuana operations; results of scientific research; uninsured
risks; regulatory changes; difficulties in construction or in
obtaining qualified contractors to complete construction or
conversion of facilities; availability of production facilities;
timeliness of government approvals and the granting of permits and
licenses; changes in prices and costs; actual operating and
financial performance of facilities; equipment and processes
relative to specifications and expectations; as well as the other
risk factors set out in the Company's annual information form and
other filings with the applicable Canadian securities regulators,
which may be viewed at www.sedar.com. Actual results may differ
materially from those expressed or implied by such forward-looking
statements
"Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release."
SOURCE Emerald Health Therapeutics, Inc.